Eric Schmidt
2021
In 2021, Eric Schmidt earned a total compensation of $3.5M as Chief Financial Officer at Allogene Therapeutics, a 39% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $180,500 |
|---|---|
| Option Awards | $1,963,489 |
| Salary | $475,000 |
| Stock Awards | $839,973 |
| Total | $3,458,962 |
Schmidt received $2M in option awards, accounting for 57% of the total pay in 2021.
Schmidt also received $180.5K in non-equity incentive plan, $475K in salary and $840K in stock awards.
Rankings
In 2021, Eric Schmidt's compensation ranked 3,874th out of 12,415 executives tracked by ExecPay. In other words, Schmidt earned more than 68.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,874 out of 12,415 | 69th |
Division Manufacturing | 1,587 out of 5,508 | 71st |
Major group Chemicals And Allied Products | 650 out of 2,378 | 73rd |
Industry group Drugs | 578 out of 2,099 | 73rd |
Industry Biological Products, Except Diagnostic Substances | 153 out of 449 | 66th |
Source: SEC filing on April 26, 2022.
Schmidt's colleagues
We found four more compensation records of executives who worked with Eric Schmidt at Allogene Therapeutics in 2021.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Allogene Therapeutics CEO David Chang receives $13M in 2018
April 24, 2019